Plasma levels of phosphorylated tau and neurofilament light chain as potential biomarkers for Alzheimer’s disease: A biochemical analysis in Pakistani population

[1]  T. Golde.  Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers , 2022, Neurotherapeutics.

[2]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[3]  F. Imtiaz,et al.  History in perspective: How Alzheimer's Disease came to be where it is? , 2021, Brain Research.

[4]  A. Ruiz,et al.  The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening , 2021, Alzheimer's research & therapy.

[5]  Chris Lynch,et al.  World Alzheimer Report 2019: Attitudes to dementia, a global survey , 2020 .

[6]  K. Blennow,et al.  Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease , 2020, Annals of clinical and translational neurology.

[7]  K. Blennow,et al.  Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected , 2020, EMBO molecular medicine.

[8]  C. Enzinger,et al.  Serum neurofilament light chain , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[9]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[10]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[11]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[12]  K. Blennow,et al.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration , 2020, Nature Medicine.

[13]  K. Blennow,et al.  Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid-positive individuals , 2019, Alzheimer's & dementia.

[14]  K. Blennow,et al.  Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. , 2019, JAMA neurology.

[15]  S. Burnham,et al.  Blood-based molecular biomarkers for Alzheimer’s disease , 2019, Molecular Brain.

[16]  J. Trojanowski,et al.  Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders , 2019, JAMA neurology.

[17]  Wei‐Ju Lee,et al.  Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease , 2018, Scientific Reports.

[18]  A. Alonso,et al.  Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability , 2018, Front. Cell. Neurosci..

[19]  K. Fliessbach,et al.  Serum neurofilament light chain in behavioral variant frontotemporal dementia , 2018, Neurology.

[20]  W. M. van der Flier,et al.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes , 2018, Annals of neurology.

[21]  K. Blennow,et al.  Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease , 2018, Alzheimer's Research & Therapy.

[22]  C. Jack,et al.  NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[23]  J. Hardy,et al.  Alzheimer's disease , 2018, European journal of neurology.

[24]  E. Westman,et al.  Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease , 2017, Neurobiology of Aging.

[25]  T. Tokuda,et al.  Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome , 2017, Molecular Neurodegeneration.

[26]  K. Blennow,et al.  Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology‐based cohort , 2017, European journal of neurology.

[27]  M. Sabbagh,et al.  Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer’s Dementia: Findings in Two Cohorts , 2017, Front. Aging Neurosci..

[28]  S. Ourselin,et al.  Neurofilament light chain: a biomarker for genetic frontotemporal dementia , 2016, Annals of clinical and translational neurology.

[29]  K. Blennow,et al.  Plasma β-amyloid in Alzheimer’s disease and vascular disease , 2016, Scientific Reports.

[30]  R. Petersen,et al.  Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials , 2015, Alzheimer's & Dementia.

[31]  M. Wasay,et al.  Validation Study of the Mini-Mental State Examination in Urdu Language for Pakistani Population , 2015, Alzheimer's & Dementia.

[32]  Blaine R. Roberts,et al.  Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease , 2014, Alzheimer's & Dementia.

[33]  Ming-Jang Chiu,et al.  Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease. , 2013, ACS chemical neuroscience.

[34]  Ludwig Kappos,et al.  Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases , 2013, PloS one.

[35]  Henrik Zetterberg,et al.  Plasma tau levels in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[36]  E. Mossello,et al.  Management of patients with Alzheimer’s disease: pharmacological treatment and quality of life , 2012, Therapeutic advances in chronic disease.

[37]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[38]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[39]  K. Blennow,et al.  Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment , 2010, Neurobiology of Aging.

[40]  R. Petersen,et al.  Alzheimer's disease and mild cognitive impairment. , 2007, Neurologic clinics.

[41]  C. Mariani,et al.  Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairment , 2006, Neurobiology of Aging.

[42]  J. Rabe-Jabłońska,et al.  [Affective disorders in the fourth edition of the classification of mental disorders prepared by the American Psychiatric Association -- diagnostic and statistical manual of mental disorders]. , 1993, Psychiatria polska.

[43]  G L Odenheimer,et al.  Management of Patients with Alzheimer's Disease , 1991, Pharmacotherapy.

[44]  H. González,et al.  Alzheimer's disease. , 2019, Handbook of clinical neurology.

[45]  D. Holtzman,et al.  Amyloid-β and Tau at the Crossroads of Alzheimer's Disease. , 2019, Advances in experimental medicine and biology.

[46]  K. Blennow,et al.  Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. , 2012, Journal of Alzheimer's disease : JAD.

[47]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.